Eight FAK inhibitors have entered clinical trials; however, only modest clinical activity has been achieved when these drugs are tested as single agents for cancer treatment.91,92 Merlin deficiency predicts FAK inhibitor sensitivity,93 but more biomarkers for FAK-targeting therapies are still needed. This evidence concerns the gene PTK2 and cancer.